229 results about "Thrombolysin" patented technology

The present invention relates to methods for the diagnosis and evaluation of stroke and stroke sub-type. A variety of bio-markers are disclosed for assembling a panel for such diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects: the invention provides methods for early detection and differentiation of stroke subtypes, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for hemorrhagic transformation after thrombolyic therapy. Methods are disclosed that provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Devices and methods are provided to administer treatment to walls of either naturally occurring cavities or cavities generated by the resection of tissue such as tumors, and to ensure better tissue contact of the device resulting in more effective treatment methods. A device may include a rigid outer surface, that can be brought into firm engagement with the tissue of body cavities by applying suction through channels in the head and stem portion of the device. Methods to treat conformed body cavities tissues may use individual or combination of physical agents including radiation, heat, cold, electrofrequency or chemical agents, such as thrombolytic and cytostatic medications. Systems may include devices described in the invention and sources to provide suction and / or other described means to enhance body tissue conformance to a non-deformable and / or non-distensible body.

The invention teaches methods and compositions for removing thrombi lodged in the microvasculature of an organ. To remove the thrombi, the organ may be perfused, flushed or washed with a suitable perfusion solution to which a sufficient amount of a thrombolytic agent, such as Streptokinase, has been added. The perfusing, flushing or washing process of the organ with the thrombolytic agent will promote thrombolysis on existing thrombi, prevent the formation of new thrombi in the organ, and / or open the vasculature of the organ thereby decreasing vascular resistance and increasing flow. The method of the invention may be practiced using an organ perfusion apparatus that would allow the viability of the organ to be sustained and / or restored upon perfusion with a thrombolytic agent.

The invention discloses a fungal fibrinolytic enzyme and a preparation method thereof. The fungal fibrinolytic enzyme is prepared by taking a Cordyceps militaris strain as a strain and performing liquid fermentation culture, separation and purification. The relative molecular weight of the fibrinolytic enzyme is about 21,000. The Cordyceps militaris fibrinolytic enzyme has good thrombolytic performance, is free from obvious acute toxicity, has prospects for clinical trial, development and application, and adds a new member to a rare fibrinolytic enzyme family. Particularly, a preferable fibrinolytic-enzyme Cordyceps militaris strain C.LSG-1 obtained through severe screening is rough in growth conditions, short in enzyme production cycle and capable of harvesting a large amount of Cordyceps militaris mycelium during enzyme production, and is the strain excellent in production performance. The Cordyceps militaris fibrinolytic enzyme is an extracellular enzyme which is particularly beneficial to subsequent separation and purification during preparation. The fungal fibrinolytic enzyme takes corn protein with extensive sources as a main culture medium, thereby having low cost for raw materials and providing a novel way for developing and utilizing the prior resources.

An apparatus and method for automatically lysing a clot to recanalize vessels using ultrasound, with or without nanoparticles, microbubbles, thrombolytic drugs or other agents, is described herein. At least one ultrasound transducer with a specified geometry, bandwidth and / or transmit pulse characteristics can generate a more uniform 3-dimensional volume of defocused acoustic energy into a target area of the body. When an agent (such as, but not limited to, microbubbles) is used to lyse a clot, a certain level of ultrasound energy may be desired in order to effect certain actions or states of the agent. Bone attenuation may present an issue inhibiting sufficient ultrasound energy from reaching the agent in order to attain the desired agent action. The relative patient dimensions and location of the clot may also present an issue.

The invention discloses a synergist for thrombolysis and its preparation method, which primarily adopts widely available P11protein as synergist for thrombolysis and other medicine. The synergist can enhance the activity of drugs for thrombolysis, improve thrombolysis effect thereby reducing medicamentous consumption and relieve adverse side effect, and reducing cost.

The invention discloses a fusing protein with plasminokin and anticoagulant function and DNA sequence to code the fusing protein, carrier with the DNA sequence and making method of fusing protein, which provides the application of fusing protein to prepare functional drug with peptide segment of continuous amino acid sequence as connecting structure, wherein the fusing protein connects 10-12 amino acids in the 55-66th amino acids sequence at IIIC end of hirudin with r-PA as t-PA bobbing mutant.

A Chinese medicine in the form of treating vasculitis, phlebitis, phlebothrombosis, lymphangitis, Raynaud's disease, etc is prepared from 6 Chinese-medicinal materials including pangolin scales, red sage root, dahurian angelica root, Chinese angelica root, etc through decocting four of them twice, concentrating the decoction, mixing with the powder of others, drying, pulverizing, sieving and loading in capsules.

The invention provides a thrombus thrombolysis and clearing device and a use method thereof, and relates to the technical field of a medical appliance. The invention aims at solving the problems thatan existing thrombus clearing device is difficult to clear the thrombus on the vascular wall, so that the thrombus clearing is unthorough. A thrombus suction head in the thrombus thrombolysis and clearing device provided by the invention is arranged on a fixed cutter holder and is rotationally connected with the fixed cutter holder; a transmission tube is arranged in an outer tube in a sleeved way; the end, provided with a through hole, of the transmission tube extends out of the outer tube; a liquid cavity bag is arranged on the outer tube wall of the outer tube between a baffle edge and a baffle ring; a sliding seat is arranged on the transmission tube in a sleeving way and is glidingly connected with the transmission tube; the sliding seat is positioned between the baffle edge and the baffle ring; and a thrombus breaking cutter is fixedly arranged between the fixed cutter holder and the sliding seat. According to the thrombus thrombolysis and clearing device, pressurized normal saline or thrombolysis medicine is sprayed out from the liquid cavity bag to break the thrombus; meanwhile, a driver drives the transmission tube to rotate at a high speed; the thrombus breaking cutter onthe sliding seat is driven to perform rotary cutting on the thrombus; and the tensioned thrombus breaking cutter can scrape away the thrombus on the vascular wall. The thrombus thrombolysis and clearing device and the use method provided by the invention are applied to the field of medical care.

A freeze-dried preparation of recombinant glucokinase in the form free dried powder, injection, lipoplasm, or microcapsule for thrombolytic purpose contains the glucokinase with mutation of amino acids at positions 7, 3 and 43, and one or more of mannitol, phosphate, EDTA and sodium chloride. Its preparing process is also disclosed.

The invention discloses a cDNA sequence and an amino acid sequence of coding lugworm fibrinolytic enzyme which are respectively shown in SEQIDNo.1 and SEQIDNo.2 in a sequence table, and belongs to the field of medical biological engineering. The cDNA sequence has the beneficial effects that according to the cDNA sequence of the lugworm fibrinolytic enzyme, the coding gene of the fibrinolytic enzyme can be cloned from digestive tract tissue of lugworm, and can be expressed in a prokaryotic expression system or a eukaryotic expression system through a gene recombination technology. The recombinant lugworm fibrinolytic enzyme has plasminogen activation activity, and can be used as a new thrombolytic medicament in genetic engineering.

The present invention relates to one kind of and its culturing and preparing process. The plasmin is prepared with N. sitophila strain No. 17 in the preservation number of CGMCC No. 1836, and through fermentation, separation and purification. It consists of two subunits of molecular weight 30000 and 15500 separately and isoelectric point of 7.9+ / -0.2. The plasmin has high thrombolysis performance, no bleeding activity, no blood coagulating activity and no obvious acute toxicity, and thus possesses clinical test, development and application foreground. The plasmin of the present invention is one kind of extracellular enzyme, and is favorable to post separation and purification. Its preparation adopts wheat bran and soybean residue as main culture medium material, and thus has low material cost.

The invention discloses an ultrasound contrast agent and a drug and a gene carrier targeted ultrasound contrast agent, which contain gas microbubbles with a diameter of 0.6 microns to 10 microns. Composed of body and surfactant, the surface is positively charged. Gas microbubbles are hollow, containing non-halocarbon gases such as air and nitrogen. Emulsion copolymerization of acrylic acid and its derivatives is carried out by emulsion copolymerization method. With the participation of surfactants, the surface tension between the gas phase and the liquid phase is adjusted so that the gas phase enters the polymer emulsion microbubbles. The gas microbubbles that are also drugs and gene carriers targeting ultrasound contrast agents contain polylysine or polyamino acids on the basis of the gas microbubbles of the above-mentioned ultrasound contrast agents, with active functional groups, and the groups are compatible with some gene plasmids The group coupling of the gas microbubbles couples the carboxyl groups of the gas microbubbles with GP II b / IIIa and other thrombus or anti-thrombotic or thrombolytic substances antibodies to make gas microbubbles carrying antibodies such as IIb / IIIa; the gas microbubble-wrapped anti The tumor drug is broken under the action of ultrasound, and the drug is released locally in the tumor.

The invention discloses a medicine eluting balloon catheter with a function of thrombus aspiration and vasodilatation, and belongs to the field of medical device. The catheter structure comprises a balloon cavity 1, an auxiliary cavity 2, a RX port 3, a guide wire cavity 4, a developing ring 5, a suction cavity 6 and a Y-type connector 7. The balloon cavity is in the outermost layer of the suctioncatheter, the auxiliary cavity 2 is on the inner wall of the suction cavity 6, and the guide wire cavity 4 is on the distal end inner wall of the suction cavity 6. The medicine eluting balloon catheter is used for medicine thrombolysis by injecting thrombolytic medicine into the suction cavity 6. The invention of the medicine eluting balloon catheter is set an auxiliary chamber on the inner wallof the suction cavity 6, applying the improved in vitro ultrasonic assisted thrombolysis (ETUS) function, and a small metal microporous cylinder is placed in human body by the auxiliary cavity 2 conveying system; the medicine eluting balloon catheter reflects multiple direction ultrasonic wave through in vitro ultrasonic probe ultrasound and porous cylinder to amplify ultrasonic cavitation effect,improving the efficiency of broken bolt, and feeds into the interference wire through the auxiliary cavity 2 to break the bolt with mechanical force.

The present invention relates to a novel microorganism Streptomyces megasporus SD5. The present invention also relates to a process for the isolation of said Streptomyces megasporus SD5. The invention also relates to a novel fibrinolytic enzyme actinokinase extracted from said microorganism and to a process for the extraction of said enzyme. In another aspect, the invention also pertains to a method for the treatment of thrombolytic disorders using said enzyme.

The invention relates to a preparation method of spirulina kinase-rich health-care food. The preparation method comprises the following steps: 1) adding shell-broken spirulina into water to obtain spirulina fermentation substrate and sterilizing; 2) inoculating the spirulina fermentation substrate with bacillus subtilis, and performing deep liquid ventilation and fermentation; 3) inoculating fermented liquor with saccharomycetes, and performing low-temperature standing and fermentation; and 4) performing low-temperature vacuum concentration on the standing and fermented liquor, drying and crushing, thus obtaining the spirulina kinase-rich health-care food. The invention further discloses a spirulina kinase health-care food prepared by adopting the spirulina kinase fermentation product. The spirulina kinase health-care food not only has higher spirulina kinase activity, but also the finished spirulina has small fishy smell, is good in mouthfeeling, and is easily accepted by people. Compared with the traditional spirulina tablets, the thrombolysis and thrombus preventing, blood lipid regulation and hemorrheology change characteristics can be greatly improved.

The invention discloses a fibrinolytic activated protein from cantharis, a preparation method and an application thereof. In the invention, the single-component protein with fibrinolytic activity is extracted from the cantharis, and the molecular weight of the protein is 95.5KD; and the protein has the advantages of easy purification and batch preparation, stronger fibrinolytic activity, high specific activity, no toxicity, small molecular weight and low antigen reaction, thus being an ideal plasmin preparation raw material as well as an ideal thrombolytic drug. The invention further discloses the preparation method of the fibrinolytic activated protein and the application of the same for preparing the drug for treating thrombotic disease.

A new human polypeptide, a cDNA encoding the same and a pharmaceutical use of it. The polypeptides of the present invention possess hematopolesis regulating activity, tissue generation / regeneration activity, activin / inhibin activity, chemotactic / chemokinetic activity, hemostatic and thrombolytic activity, and receptor / ligand activity, therefore, they are expected to be useful for prevention and / or treatment of various diseases.

The invention relates to the technical field of medical apparatuses and instruments, in particular to a universal thrombus smashing and extracting device with biomimetic jellyfish contraction and expansion functions. The device comprises a spraying mechanism used for spraying a thrombolytic drug, a thrombus smashing and extracting mechanism used for guiding thrombus out and connected with the spraying mechanism, a guiding mechanism used for pushing the spraying mechanism to go into a human body lumen and a power mechanism used for driving the guiding mechanism to move. According to the universal thrombus smashing and extracting device with the biomimetic jellyfish contraction and expansion functions, the spraying mechanism can go into the human body lumen by means of the guiding mechanism,then the thrombolytic drug is sprayed by the spraying mechanism so that thrombolysis can be conducted, the thrombus is smashed and extracted by the thrombus smashing and extracting mechanism, operation is convenient, the thrombus elimination speed is high, and the efficiency is high.

A composite medicine used also as the additive of cosmetics and health-care food for lowering blood viscosity, dissolving thrombus, and regulating blood pressure, blood sugar and blood fat is prepared through extracting to obtain L-polybasic metallothionein (L.pMT), lumbrikinase and antibacterial peptide, proportionally mixing it with the extracts of astragalus root and red sage root, thiooctanoic acid and 1,6-pectose-zinc biphosphate, and dispensing.

The invention provides a thrombolytic active substance extracted from a Guizhou fermented blank bean and a product thereof. The fermented blank bean is a folk favorite conventional food in Guizhou. The substance is prepared by taking soybeans as a raw material and carrying out microorganism fermentation, and the flavor tastes sweet but smells smelly. People think that the food stimulates the appetite and is favorable for digestion, and the substance is generally edible and a favorite food of people in Guizhou for a long time. The natural thrombolytic active substance extracted from the Guizhou conventional fermented blank bean and the product thereof have obvious thrombolytic activity, can reduce blood viscosity, promote blood circulation, and are used for treating and preventing heart cerebrovascular diseases such as thrombus diseases and the like. The thrombolytic active substance has the biochemistrical characteristics that: molecular is 28KD; the optimal pH is 8.0; the substance is stable below 50 DEG C, and is not stable in the stomach environment; and the substance has the hrombolytic effects of activating plasminogen to be converted into fibrinoclase, and directly dissolving fibrin in the thrombus.

A vena cava filter device capable of releasing a thrombolytic drug is characterized in that a drug release head with a plurality of irregular holes is arranged in the center of a filter, the drug release head and a drug conveying pipe are connected and arranged in a filter body connecting pipe, and one end of the drug conveying pipe is provided with a drug injection hole. According to the vena cava filter device, thrombi are stopped by the vena cava filter, the thrombolytic drug is injected into the drug conveying pipe in the a filter body connecting pipe through the drug injection hole, and if the thrombi are stopped by the vena cava filter, the thrombolytic drug is directly injected to the thrombi through the irregular holes; it is not needed that venipuncture is carried out on a patient again to achieve thrombolysis, so that secondary injuries to the patient are reduced and risks brought by venipuncture to the patient are avoided; the vena cava filter device has the dual effects of stopping the thrombi and achieving thrombolysis.

The invention discloses a water gel material with thrombin responsive thrombolysis capability and a preparation method thereof, the water gel material with thrombin responsive thrombolysis capability is prepared as follows thrombin substrate peptide is used as a crosslinking agent, water gel is formed by free radical polymerization, meanwhile the water gel coats thrombolysis active molecules, and the thrombolysis active molecules only can significantly release and play fibrinolytic function. The material has the thrombin responsive thrombolysis capability, avoids the defect of a series of complications caused by the long-term exposure of reactive molecules of traditional thrombolysis materials, and has application prospect in the aspect of human implanted blood contact materials.

The invention relates to a method for preparing a thrombolytic medicament Reteplase (rPA) directly through an escherichia coli expression system without inclusion-body renaturation. A gene segment of the rPA is obtained through PCR amplification, and is cloned into a vector pET40b to construct a pET40b-rPA recombinant plasmid, and the rPA is made to perform fusion expression with the protein disulfide isomerase DsbC in the vector pET40b. The recombinant plasmid is transformed into the escherichia coli BL21 (DE3), and induction expression conditions of IPTG and lactose are respectively established optimally. The obtained target fusion protein is mainly expressed by soluble components, and is purified by Ni-NTA affinity chromatography and processed by a Xa factor (or formic acid or thrombin) to form the high-purity rPA target protein. Fibrin plate method detection results show that the fusion protein DsbC-rPA obtained by the method and the rPA protein obtained by removing a label and purifying have obvious thrombolytic activity.

The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below:wherein the definitions of T, Q, R1 and R2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting / antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

The present invention relates to the use of plasminogen in the dissolution of fresh and old thrombus. Compared with other existing thrombolytic drugs, the plasminogen of the present invention can specifically dissolve thrombus without causing side effects such as bleeding. The drug of the present invention also has the advantages of dissolving both fresh and old thrombus, with a long half-life and controllable thrombolytic strength. Therefore, plasminogen may become a brand-new strategy for dissolving thrombus in vivo.